The system was the first to allow people with diabetes to monitor blood glucose without fingersticks.
Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, giving US patients with diabetes access to technology that has been used in Europe for years.
The company announced the approval Friday in a statement. FDA’s action comes 10 months after it approved the Freestyle device with a 10-day sensor, offering people with diabetes the ability to monitor blood glucose without finger sticks. The Freestyle Libre is factory calibrated.
“At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, the company’s senior vice president for Diabetes Care. “With the new FreeStyle Libre 14-day system, people with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition.”
The round sensor is placed on the upper arm; a thin filament inserted just under the skin takes blood glucose readings once a minute. For monitoring, users hold a scanner over the sensor to transmit the data.
In its statement, Abbott said the system requires a 1-hour warmup and offers improved accuracy compared with the 10-day sensor approved last year. The 14-day system has a mean absolute relative difference, or MARD, of 9.4, compared with 9.7 for the 10-day system.
The company said the 14-day system will be available “in the coming months” with a prescription at pharmacies and durable medical equipment suppliers.
The 14-day system launched in Europe in 2014 and is available in 30 countries.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen